| Identification | Back Directory | [Name]
2-Thiopheneacetamide, N-[(4-methoxyphenyl)methyl]-N-(3,4,5-trimethoxyphenyl)- | [CAS]
2305757-96-2 | [Synonyms]
VII-31
2-Thiopheneacetamide, N-[(4-methoxyphenyl)methyl]-N-(3,4,5-trimethoxyphenyl)- | [Molecular Formula]
C23H25NO5S | [MDL Number]
MFCD32857155 | [MOL File]
2305757-96-2.mol | [Molecular Weight]
427.51 |
| Chemical Properties | Back Directory | [Boiling point ]
598.8±50.0 °C(Predicted) | [density ]
1.228±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
0.20±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways[1]. | [in vivo]
VII-31 inhibits the tumor progression in vivo, while showing no obvious toxicity to mice[1]. | Animal Model: | Mice bearing MGC803 xenograft tumors[1] | | Dosage: | 50, 100, 150 mg/kg | | Administration: | Subcutaneous injection; daily for 28 days | | Result: | The mice had a much smaller tumor compared with vehicle control. The tumor volumes of middle/high dose treated mice at certain time points were evidently decreased comparing with untreated group. |
| [References]
[1] Dong-Jun Fu, et al. Discovery of Novel Tertiary Amide Derivatives as NEDDylation Pathway Activators to Inhibit the Tumor Progression in Vitro and in Vivo. Eur J Med Chem. 2020 Apr 15;192:112153. DOI:10.1016/j.ejmech.2020.112153 |
|
|